1.P.139 The cost-effectiveness of preventing initial coronary events with pravastatin: Results of the West of Scotland coronary prevention study economic analysis
To the Editor.—
I was delighted to see Donn's letter about the cost effectiveness of home management of bronchopulmonary dysplasia.1 Such contributions are vital in helping to curb the rapidly rising costs of neonatal intensive care. However, his economic analysis is flawed. By tacit assumption, he omits any consideration of the opportunity costs to the parents. To omit this presumes that the parents' time is worth little or nothing, as we often seem to indicate by the long patient waiting times in our offices.
PMH5: THE COST-EFFECTIVENESS OF QUETIAPINE IN THE TREATMENT OF SCHIZOPHRENIC PATIENTS PARTIALLY RESPONSIVE TO PREVIOUS ANTIPSYCHOTICS—AN ECONOMIC ANALYSIS OF THE PRIZE STUDY